May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Baseline Characteristics of Study Eyes Enrolled in a Longitudinal, Observational Study to Identify the Early Markers of Choroidal Neovascularization (CNV)
Author Affiliations & Notes
  • R. R. Buggage
    Pfizer, Inc., New York, New York
  • R. Silva
    AIBILI, Coimbra, Portugal
  • R. Bernardes
    AIBILI, Coimbra, Portugal
  • S. Nunes
    AIBILI, Coimbra, Portugal
  • P. Fonseca
    AIBILI, Coimbra, Portugal
  • J. Cunha-Vaz
    AIBILI, Coimbra, Portugal
  • Footnotes
    Commercial Relationships  R.R. Buggage, Pfizer, Inc, E; R. Silva, None; R. Bernardes, None; S. Nunes, None; P. Fonseca, None; J. Cunha-Vaz, Zeiss, C; Allergan, C; Eli-Lilly, C; Merck, C; Pfizer, C; Servier, C.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 285. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      R. R. Buggage, R. Silva, R. Bernardes, S. Nunes, P. Fonseca, J. Cunha-Vaz; Baseline Characteristics of Study Eyes Enrolled in a Longitudinal, Observational Study to Identify the Early Markers of Choroidal Neovascularization (CNV). Invest. Ophthalmol. Vis. Sci. 2008;49(13):285. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To describe the baseline imaging characteristics of subjects enrolled in a longitudinal, observational study to identify the morphological and/or functional features defining the earliest identifiable CNV lesion in age-related macular degeneration (AMD).

Methods: : Subjects >50 years with neovascular AMD in one eye and intermediate or large/confluent drusen with hyperpigmentation but no CNV or geographic atrophy in the fellow eye (study eye) at high risk for progression from dry to wet AMD were eligible for the study. To characterize the earliest sequence of changes occurring at the chorioretinal interface during the development of CNV the study eye was evaluated with ETDRS visual acuity, complete ophthalmic examination, fundus photography, fluorescein and indocyanine green angiography (FA, ICG-A), ocular coherence tomography (OCT), multifocal electroretinography (mfERG), fundus autofluorescence and retinal leakage analysis at baseline and, thereafter every 6 months for a period of 2 years or until CNV presence is confirmed by FA. Available baseline demographic and imaging data are reviewed

Results: : In 59 subjects (30 females, 29 males, mean age 77 years) neovascular AMD was diagnosed in the non-study on average 20.4 months prior to enrollment (range 1 month -11 years, median 12.7 months). Mean baseline visual acuity was 20/32 in the study eye and 20/200 in the non-study eye consistent with the finding of macular scarring/atrophy. Drusen (large/intermediate or confluent) seen primarily on fundus photography and/or FA and hyperpigmentation were the most common baseline findings in study eyes. Fundus autofluorescence demonstrated variable patterns of hypo and hyperfluorescence. No definitive signs of CNV such as hemorrhage, lipid deposits, retinal edema, pigment epithelial or neurosensory detachments were identified on any of study baseline imaging evaluations.

Conclusions: : Approximately 42-58% of patients CNV in one eye and age related maculopathy in the fellow eye will develop bilateral CNV within 5 years. Review of the baseline imaging of study eyes in this multimodality study demonstrated clinical findings characteristic of patients at high risk for, but, the absence of clinically recognizable CNV. Completion of this study will yield further understanding of the natural history of AMD progression.

Keywords: age-related macular degeneration • choroid: neovascularization • imaging methods (CT, FA, ICG, MRI, OCT, RTA, SLO, ultrasound) 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×